The tale of oral isotretinoin: From miracle to maligned to managed
Isotretinoin, a synthetic retinoid developed by Hoffman la Roche (Basel Switzerland) and patented in 1969, was initially intended for use as a preventive agent for skin cancer. The research at that time was being pursued by Gary Peck, a young researcher with the then National Cancer institute who was studying isotretinoin as a possible lung cancer preventive agent and in various cutaneous keratinizing disorders including psoriasis, ichthyosis and Darier’s disease. In a presentation to the dermatology research group at the University of Pennsylvania – Albert Kligman asked him about the effects on acne. This question spurred him to initiate a small clinical trial on severe recalcitrant nodular acne in 1977. In that study the clinical effect was termed miraculous. Despite known issues with teratogenicity, it was FDA approved in 1982. Since then, while being the salvation for acne sufferers globally it has also been the target of misinformation, litigation and increasing scrutiny from the public, clinicians and regulatory authorities. In 2006, the prescribing of isotretinoin was even more tightly regulated and managed in the USA with introduction of iPledge. Nevertheless, it became and remains the unsurpassed standard of acne efficacy to the present day, 41 years after approval. In this presentation, I discuss the development of oral isotretinoin with acknowledgment to the people pivotal to its emergence and its ongoing evolution.
What’s Next in Psoriasis Therapy
The lecture titled "What's Next in Psoriasis Therapy" delves into advancements in the treatment of psoriasis. It explores the promising prospects of two new topical therapies, recently approved rolflumilast, and soon to be approved, tapinarof, which exhibit remarkable efficacy in managing plaque psoriasis. Additionally, the lecture highlights ongoing research into oral TYK2 inhibitors, showcasing their potential as a game-changing approach for psoriasis management. By shedding light on these innovative treatments, the lecture provides valuable insights into the future of psoriasis therapy, offering hope for improved quality of life and relief for those affected by this chronic skin condition beyond biologics.
The Good, The Bad, The Untapped - Facial Cosmetics in Skin of Colour
A round up of the most requested cosmetic procedures and therapies used in patients across skin tones and ethnicities - plus some pearls to adopt, pitfalls to avoid and a peek at what's ahead.
Q & A
Impact of current gaps and misconceptions in photoprotection on dermatologic health for skin of all color
It has long been known that UV radiation harms skin, although most focus has been on those with lighter skin tones (Fitzpatrick skin types I-III), studies are now showing the negative impact of visible light on skin health, particularly in individuals with skin of color (Fitzpatrick skin types IV-VI). This session will highlight the misconceptions about sunlight-related skin damage, highlight the impact of visible light on skin health, and the need for photoprotection in skin of all color.
The Reason is Clear: Elevating Standards of Care in Psoriasis and Atopic Dermatitis
Given the evolution from traditional systemic therapies to advanced treatment options in both psoriasis and atopic dermatitis, physicians can aspire to gain control on the disease and optimize patient outcomes. This session will highlight the importance of advanced therapies in treating to higher standards of care and the significant impact it can have on patients’ quality of life.
In collaboration with:
Visualizing Skin Health: Navigating The State of Dermatoimaging in 2023
In this presentation, two teledermatology experts will give a thorough overview of Dermatoimaging. They will cover its techniques, advanced methods, best practices, and how artificial intelligence and machine learning are being used to deploy and assess skin images. The speakers will explain how these technologies aid in image analysis, diagnosis, and pattern recognition, ultimately enhancing clinical decision-making. Additionally, they will discuss the innovative applications of Dermatoimaging, such as monitoring treatment progress, teledermatology, and data-driven research advancements.
In collaboration with:
Navigating the Skincare Maze: A Scientific Guide to Choosing the Right Products for the right patients
Navigating the ever-evolving skincare landscape to recommend the most effective products to patients can often feel like maneuvering through a maze. This open session aims to serve as a guide to help physicians make informed choices rooted in scientific evidence.
This dynamic session will delve deep into the latest advances in dermatological science, examining the published studies and clinical evidence surrounding antioxidants and retinoids in skincare. The goal is to shed light on the pivotal role these ingredients play in promoting skin health and addressing various skin concerns. Dr. Sam Hanna and Dr. Sonya Abdulla will bring their clinical expertise to explore the art and science of selecting the right products that best cater to individual patient needs.
Join this session to enhance your understanding of the latest developments in the skincare field and learn practical tips for making informed, scientifically-backed choices in product recommendations for patients.
The Impact of Oat Therapy: Eczema and Beyond
This session will highlight the history of oat, the data supporting the mechanism of action of oat in emollients and the clinical efficacy and safety of its use in various skin conditions.
Immunology continues to touch all of our lives as dermatologists. The research and development pipeline remains exciting into the year 2023. We have moved beyond the large-scale “biologics era” in psoriasis and atopic dermatitis. 2022-2023 (and beyond) was the year of the big “biosimilar switch”.
We are seeing the development of increasingly “fine tuned” molecules for these conditions, with some exciting new launches in Canada within the past year. JAK Inhibitors have officially been prescribed in our practices for two years now in atopic dermatitis. We now have good “real world” experience with these molecules. We are looking forward to the potential launches of JAK Inhibitors in the areas of alopecia areata and vitiligo soon.
Conditions such as vitiligo, alopecia areata, hidradenitis suppurativa, prurigo nodularis have shifted into the focus for much of the new dermatology pharmaceutical industry research and development.
We are seeing unique molecules focusing on the microbiome or with unique methods of delivery. This presentation will provide an overview on what dermatology drugs are new to the market, the status of current clinical trials and an overview of the current landscape in dermatology drug development.
New and Emerging Therapies for Vitiligo
New and Emerging therapies for vitiligo will involve updating dermatologists on the impacts on well-being and mental health, looking at new JAKI and other immune-based treatments. We will also update you on ways to address melanocyte pathology using phototherapy, excimer laser, and new melanocyte-focused treatments.
From A (Artificial) I (Intelligence) to A (Atopic Dermatitis) I (Introspective): A Holistic Patient Experience
With the use of AI software, we will bring case studies to life. The AI will generate an image which illustrates patients' introspective thoughts and feelings at two different points in their treatment journey.
Seb D or Not to B? That is the Clinical Question
- Analyze and review the current understanding of the pathogenesis involved in seborrheic dermatitis
- Discuss the heterogenous clinical presentations of seborrheic dermatitis and other similar inflammatory/pruritic skin conditions
- Examine the benefits and challenges of current treatment options for seborrheic dermatitis and explore future treatment options
Summary Description: Join us on a Shakespearean exploration where the many facets of seborrheic dermatitis will be brought to the stage. In the opening act, our expert moderator/director, Dr. Sam (Hamlet) Hanna, will review our present understanding on the multifactorial pathogenesis of this common chronic inflammatory condition. In the following acts, our expert speakers, Dr. Melinda Gooderham, Dr. Daniel Wong, and Dr. Geeta Yadav, will discuss varying clinical points of perspective on the commonalities and differences between seborrheic dermatitis and other inflammatory/pruritic skin conditions with respect to the pathophysiology and clinical presentations. This open session will also examine the efficacy, safety, and tolerability of current topical treatments. The final act will explore new developments in topical treatment for seborrheic dermatitis. Those in attendance at the theatre will gain a better understanding of the treatment strategies and unmet needs in the management of patients with this common chronic inflammatory dermatosis.
Managing Pain for in-clinic dermatology and aesthetic procedures
The standard of care in managing pain for short-term dermatology and aesthetic procedures is well established. However, there is a new paradigm for pain management for in-clinic dermatology and aesthetic procedures that you may not yet know.
- Discuss the pros and cons of treatment options of pain management of short-term in-clinic dermatology and aesthetic procedures
- Educate and share clinical experience on the efficacy and safety of inhaled analgesic for in-clinic dermatology and aestshetic procedures
Unmet Needs in Atopic Dermatitis: Towards a Mechanistic Understanding
- Describe the burden of uncontrolled atopic dermatitis in different patient populations
- Summarise recent translational discovery underlying itch, and the pathophysiology and phenotypes of AD
There are unmet needs in the management of atopic dermatitis (AD), especially in underserved areas. Itch is the most universal symptom in patients with AD and is typically the most burdensome symptom. When asked about the frequency of itch in 110 patients with AD in Canada surveyed by CSPA and Eczema Quebec, over 70% mentioned that they experienced itch everyday in the past week. With recent translational discoveries, there have been substantial advances in the understanding of the phenotypes of AD, the sensation of itch and its molecular pathways from skin to brain. This Open Session will review the burden of uncontrolled AD in different patient populations, the molecular mechanisms underlying the pathophysiology of AD and the sensation of itch.
The Dynamic Skin Barrier: Cleanse, Moisturize, Treat & Protect
When you think of the skin what comes to mind? What active ingredients do you recommend to support your patients skin health? The skin barrier proactively works to protect the skin's moisture balance and integrity through several integrated functions. This evolves the skin barrier conversation beyond a brick-and-mortar structure to the sophisticated and complex Dynamic Skin Barrier while reviewing evidence-based ingredient science that matters to you and your patients.
Challenges in Treating Skin Reactions in Oncology Patients Receiving Targeted Therapy
The aim of the CaSMO group is to address challenges in treating skin reactions in oncology patients receiving cancer therapies by developing practical clinical tools. These tools aim to support all healthcare providers treating oncology patients and survivors, including physicians, nurses, pharmacists, and advanced providers.
In this 30-minute presentation, Maxwell Sauder will address recommended CaSMO approaches to four targeted therapy-related cutaneous adverse events: 1) Papulopustular eruptions, 2) xerosis, 3) Paronychia, 4) Hand and foot skin reaction.
CrossTalk Live: Interdisciplinary conversations on the safety of JAK inhibitor use in moderate to severe atopic dermatitis
At the end of this session participants will be able to:
- Integrate the interdisciplinary perspective on the use of JAK inhibitor in moderate to severe atopic dermatitis and concern for risk of infections and vaccination requirements.
- Communicate patient counselling tips on mental health matters that arise with itch when managing moderate to severe atopic dermatitis.
Join this engaging talk-show session with a nationally recognized host who engages in real-world conversations with two leading interdisciplinary experts, an infectious disease specialist and a psychiatrist, on two hot topics in atopic dermatitis, namely risk of infections with JAK inhibitor use and psychodermatology. Learn these specialists’ perspective on practical questions such as what vaccinations are required and how to counsel the patient on the psychological complications itch brings. Walk away with tips on what is important to communicate to your patients during a short office visit regarding these concerns to improve patient care.
PASI or PLAY: Exploring the correlation between PASI score and patient satisfaction in a clinical setting
After attending this program, attendees will be able to:
- Evaluate the correlation between PASI score and patient satisfaction/quality-of-life in the clinical setting
- Discuss how different factors influence treatment decisions in the management of psoriasis
There are limited data investigating the correlation between PASI score and patient satisfaction and quality of life. In this session, Dr. Perla Lansang will present a patient case and explore potential relationships between these factors through a panel discussion with Dr. Perry Grewal and Dr. Vimal Prajapati. The session will involve audience participation throughout the session with polling questions, and conclude with an opportunity for the audience to pose questions and/or provide their insights.
Southern Exposure: Clascoterone real-world experience in the U.S
After attending this program, attendees will be able to:
- Understand and describe the clascoterone phase 3 and extension trial data, and how it can be applied to the Canadian acne treatment landscape
- Gain perspective and understanding into the real-world treatment of acne with clascoterone based on U.S. experience
With the evolving acne treatment landscape and the recent Health Canada approval of acne therapy clascoterone, there remains a need for clinical discussions around the real-world use of current acne treatments. In this session, Dr. Todd Plott will provide insight into the experience of treating acne in the United States, including the use of clascoterone, through presentation and case discussion. The session will conclude with an opportunity for the audience to pose questions to Dr. Plott.
Health Canada Proposed Amendments to Cosmetic Regulations
Breaking Barriers: Therapeutic Advances in Neurofibromatosis Treatment
- Review indication, safety and efficacy of selumetinib
- Review management of acneiform eruption from selumetinib
- Review management of paronychia from selumetinib
New and Emerging Therapies for Prurigo Nodularis
- Briefly review the immunopathogenesis of prurigo nodularis
- Discuss current treatment strategies
- Examine recently approved and emerging therapies
Something New, Something Old, Something Borrowed, Something Told
Therapeutic tips and pearls from last year: conferences, journals and my practice.
- Review of a few new medication's indications
- Emphasize on some older medications dermatologic uses
- Review of few endocrinologic treatments in dermatology everyday practice
Q & A
Mucocutaneous Extraintestinal Manifestations of Inflammatory Bowel Disease
- Review the classification of common and important cutaneous manifestations of IBD by pathophysiologic origin
- Review the impact of systemic treatment of underlying IBD on some common and important cutaneous manifestations
- Update on the impact of gut selective therapy (Vedolizumab) on cutaneous manifestations - what we know so far
Dermatology + AI: The Top Three Advances in 2023
Novel Biologics for Hidradenitis Suppurativa - Then, Now and Beyond
- Overview of current biologic(s) and other therapeutics in HS
- Pipeline of therapeutics in development/pre-launch
- Challenges faced in HS drug development and funding
- How does the future of HS management look?
Melanoma: Rising Trends and Implications
- Define melanoma incidence and mortality trends across Canada by region.
- Highlight clinically relevant outcomes of patient-reported data regarding sunscreen and sun protection use by region.
- Detail patient attitudes and beliefs towards melanoma awareness and sun protection use in Canada.
Introducing DiTiDE: Impactful DE&I Initiatives for Dermatology
Q & A